HBV Cure vignet
Meeting category
Date(s)
11 Nov 2020 - 2 Dec 2020
Organizer
Silver Level Support
Sponsor logos
Gilead logo

International Workshop on HBV Cure 2020

Related Enduring Materials

Enduring Materials
Pre AASLD Session - 11 November 2020 -
Potential of new combinations to achieve functional cure for Chronic Hepatitis B
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
Rationale for including immune tolerant and low viral load patients in new drug trials
Henry Lik Yuen Chan MD, FRCP (Edin, Lond), FAASLD
Henry Lik Yeun Chan, MBChB, MD, FRCP, FAASLD, FHKCP, FHKAM
The Chinese University of Hong Kong, Hong Kong, China
How to interpret flares in HBV trials with novel agents
Pietro Lampertico, MD, PhD
University of Milan, Italy
Toxicity in new and established HBV compounds
Jordan Feld, MD, MPH
Toronto Centre for Liver Disease, Canada
Safety monitoring for different drug classes and antiviral discontinuation
Poonam Mishra, MD, MPH, FAASLD
US Food and Drug Administration, United States
Post AASLD Session - 02 December 2020 -
Update on new antiviral targets - Capsid Inhibitors
Kosh Agarwal, MD
King’s College Hospital, United Kingdom
Update on new antiviral targets - non-Capsid Inhibitors
Man-Fung Yuen, MBBS, MD, PhD, DSc
University of Hong Kong and Li Shu Fan Medical Foundation, Hong Kong
Update on new immuno modulators
Adam Gehring, PhD
Toronto Centre for Liver Disease, Canada
Update on Hepatitis Delta therapy
Robert Gish MD, FAASLD
Robert Gish, MD, FAASLD
University of California - San Diego, San Diego, United States
Update on novel combination strategies
Marion Peters, MD
Northwestern University, United States
Language